BRAF and thyroid cancer: Clinical outcomes specific to thyroid cancer were later reported in a dedicated subanalysis of a phase I trial including 14 patients with BRAF V600E-mutant metastatic thyroid carcinoma, of whom 93% had received prior radioactive iodine (57).